Companies, like people, do not often grow old gracefully. More often than not, parts stop working right, it takes more effort to achieve the same ends, and the overall pace slows down. While some accept this and do the best they can, others resort to cosmetic fixes to patch over the ravages of age. To that end, Medtronic (NYSE:MDT) seems to be handling its maturity with integrity and realism.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

A Mediocre Quarter
Medtronic's fiscal third quarter results are not likely to excite long-term investors that much. Revenue grew less than 3%, which was mostly in line with analyst expectations and overall medical device sector growth. That, then, is part of the problem with Medtronic - it has matured to a point where it no longer flies ahead of the pack. Looking at some of the details, the company's core CRM business saw revenue decline 2%, while spine grew by 2% and cardio rose better than 7%. Diabetes and surgical technologies were also solid growers (up 10% and 8%, respectively), but they are relatively small businesses for Medtronic. (For more, see Keeping Pace At Medtronic.)

Third quarter earnings quality looks a bit problematic. Although the company did beat the consensus estimate for the quarter, gross margin fell more than a full point, and operating income dropped more than 3% (with operating margin contracted two points). Like so many other companies, an unexpectedly low tax rate allowed the company to meet the earnings bogey, but the quality of that beat is low. (For more, see Strategies Of Quarterly Earnings Season.)

The Road Ahead
Continuing the theme of Medtronic's midlife crisis, the company is now facing a lot of "mature company issues." Investors are waiting to see what the company will do with its CEO transition and what the new leadership will have in mind to improve growth. That's a fair bit of uncertainty given the numerous possible pathways in health care. Will Medtronic sacrifice margins and boost R&D spending? Will Medtronic try to buy its way back into growth? Will management reposition Medtronic as more of a cash-farmer of stable businesses?

Beyond this, there are other signs of age as well. Some investors are pushing management to split the business and separate the higher and lower growth units. Along the way, management has also decided that the company is over-staffed and will be cutting a large number of jobs. That's just not something that growth companies do, so perhaps it is an acknowledgment of reality on the part of Medtronic.

In the meantime, growth prospects are looking quite a bit brighter at places like Edwards Lifesciences (NYSE:EW), Intuitive Surgical (Nasdaq:ISRG), and the more direct Medtronic rival St. Jude Medical (NYSE:STJ). What's more, Boston Scientific (NYSE:BSX) seems serious about getting its house in order and that could be a threat to Medtronic down the line. (For related reading, see Med-Tech Choice Is Simply Intuitive)

The Bottom Line
Medtronic's stock has done pretty well over the past three months and no longer looks like a great value play in the space. Abbott (NYSE:ABT) and Roche (Nasdaq:RHHBY) have similar growth worries weighing on their stocks, but look cheaper. Beyond that are turnaround plays like Boston Scientific or Nuvasive (Nasdaq:NUVA) as well as risky small-cap growth stories.

Medtronic does do an exemplary job, though, of translating revenue into free cash flow and that should not be underestimated. Medtronic also appears increasingly willing to share its cash with shareholders. All in all, then, it looks like Medtronic is navigating a difficult transition with a decent amount of skill. The downside of such a transition is that the company becomes a somewhat staid and dull dividend-payer, and as far as downsides go, that really is not too bad at all. (For more, see A Checklist For Successful Medical Technology Investment.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  2. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  3. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  4. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  5. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  6. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  9. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
Trading Center